Cargando…

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate a...

Descripción completa

Detalles Bibliográficos
Autores principales: Conte, PierFranco, Bisagni, Giancarlo, Piacentini, Federico, Sarti, Samanta, Minichillo, Santino, Anselmi, Elisa, Aieta, Michele, Gebbia, Vittorio, Schirone, Alessio, Musolino, Antonino, Garrone, Ornella, Beano, Alessandra, Rimanti, Anita, Giotta, Francesco, Turletti, Anna, Miglietta, Federica, Dieci, Maria Vittoria, Vicini, Roberto, Balduzzi, Sara, D'Amico, Robert, Guarneri, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642895/
https://www.ncbi.nlm.nih.gov/pubmed/37748109
http://dx.doi.org/10.1200/JCO.23.00790

Ejemplares similares